CJC (no DAC) + Ipamorelin (10mg)

$84.99

CJC (no DAC) + Ipamorelin is a research-grade blend combining two complementary GH axis peptides. CJC-1295 without Drug Affinity Complex is a GHRH analogue engaging the hypothalamic-pituitary axis at the GHRH receptor level. Ipamorelin is a selective GHSR-1a agonist engaging the ghrelin receptor pathway. In research settings, this combination is studied for its dual-mechanism GH axis engagement and associated downstream signaling.

BioRhex supplies CJC (no DAC) + Ipamorelin as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.

What Is CJC (no DAC) + Ipamorelin?

CJC (no DAC) + Ipamorelin is a research-grade blend combining two complementary GH axis peptides. CJC-1295 without Drug Affinity Complex is a GHRH analogue engaging the hypothalamic-pituitary axis at the GHRH receptor level. Ipamorelin is a selective GHSR-1a agonist engaging the ghrelin receptor pathway. In research settings, this combination is studied for its dual-mechanism GH axis engagement and associated downstream signaling.

BioRhex supplies CJC (no DAC) + Ipamorelin as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.

Compound Overview

This research blend is studied for its complementary engagement of two distinct GH axis receptor pathways. In vitro and preclinical models examine how this combination may influence:

• Simultaneous GHRH receptor and GHSR-1a activation in pituitary models
• GH secretion pulse amplitude in dual-pathway stimulation models
• IGF-1 axis downstream modulation
• Somatostatin-mediated GH inhibition pathway interactions
• GH axis selectivity profile relative to single-pathway agonism
All findings referenced are from controlled research environments and do not represent clinical outcomes or therapeutic claims.

History of CJC (no DAC) + Ipamorelin

Research interest in GHRH analogue and GHSR agonist combinations arose from preclinical work suggesting additive or synergistic effects on GH secretion amplitude when both receptor pathways are engaged concurrently. CJC-1295 no DAC was developed as a short-acting GHRH analogue preserving physiological GH pulse patterns, while Ipamorelin was developed for GHSR selectivity.

This combination became a research tool for studying GH axis pharmacology through a dual-mechanism approach — providing a model distinct from either single compound in isolation.

It is used in research settings to investigate complementary hypothalamic-pituitary GH axis signaling dynamics.

Molecular Structure

CJC-1295 (no DAC): Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂ | Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

Research Findings

Published and preclinical research on CJC (no DAC) + Ipamorelin covers several areas of scientific investigation, including:

  • Dual-receptor axis modeling: Studies examine combined GHRH-R and GHSR-1a engagement and downstream GH secretion profiles in experimental systems.

  • Synergistic pathway research: Research investigates additive or synergistic somatotroph GH output changes with dual-pathway activation.

  • IGF-1 downstream signaling: Laboratory models evaluate IGF-1 axis activity in response to dual-mechanism GH axis stimulation.

  • Somatostatin interaction studies: Research examines how dual-pathway activation interacts with somatostatin-mediated GH inhibition in preclinical models.

All findings referenced are from controlled, non-clinical research models and do not imply therapeutic or clinical application.

References

FAQ

What type of research is CJC (no DAC) + Ipamorelin used for?

CJC (no DAC) + Ipamorelin is used in laboratory research settings. All supplied compounds are intended strictly for in vitro and preclinical research purposes. Use is limited to controlled scientific environments.

All BioRhex compounds, including CJC (no DAC) + Ipamorelin, are manufactured in a GMP-compliant facility located in the United States.

Every batch of CJC (no DAC) + Ipamorelin undergoes third-party HPLC purity testing, mass spectrometry identity verification, and sterility testing. A Certificate of Analysis is included with every order, documenting batch-specific purity data at a ≥99% threshold.

No. CJC (no DAC) + Ipamorelin is not FDA-approved and is not intended for human or animal administration. It is supplied exclusively for laboratory research purposes.

Only qualified personnel in controlled laboratory settings following appropriate safety and handling protocols.

Research Use Only

All BioRhex compounds are supplied strictly for laboratory research purposes. Not for human or animal consumption, medical use, or therapeutic application. CJC (no DAC) + Ipamorelin is not FDA-approved for any medical purpose. Nothing on this page should be interpreted as health guidance or applied outside controlled research settings.

RELATED PRODUCTS